New strategic partnerships: our global oncology network continues to expand!

The network

Rosalind Study

Publication Date:

We’re happy to welcome new leading oncology institutions to our Rosalind Study!  

Together, we're building the world's most comprehensive database of exceptional cancer survivors, transforming individual stories of resilience into scientific breakthroughs that could redefine cancer treatment globally. 

Our new partners include: 


🇨🇦 UHN - Princess Margaret Cancer Centre, Dr. Benjamin Lok
🇫🇷 AP-HM, Dr. Alexandre Bertucci
🇫🇷 AP-HP – La Pitié Salpêtrière, Avicennes, Cochin, Saint-Louis
🇲🇶🇫🇷 CHU Martinique, Dr. Arsène Kagambega
🇮🇹 IEO - European Institute of Oncology, Dr. Lucas Mazzarella
🇮🇹 Istituto Clinico Humanitas - Rozzano (IRCCS), Prof. Matteo Simonelli
🇸🇪 U-CAN — Uppsala University Hospital, Dr. Oscar Simonson
🇪🇸 Hospital General Universitario Gregorio Marañón
🇹🇷 Gaziantep City Hospital, Prof. Hakan Hatipoğlu
🇹🇷 Bursa Medicana Hospital, Prof. Nilüfer Avcı

And the momentum continues with a significant increase in the number of identified exceptional cancer survivors. More collaborations are on the horizon, so stay tuned!  


Updated: May 25, 2026

UNTIL ALL SURVIVE.

From frontline caregivers and patients to researchers and media voices, we bring diverse perspectives together to advance cancer research. Let’s talk.

UNTIL ALL SURVIVE.

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.

©2024 Cure51, All Rights Reserved

©2026 Cure51, All Rights Reserved

Rosalind is an independent, proprietary Cure51 clinical study and is not affiliated with any external AI models or products.